Clinical Trials for RO5185426 (Vemurafenib)

4 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCPHI1328
09/05/2013
A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination with Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma
TreatmentVICCMEL1256
12/06/2012
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence
TreatmentVICCPHI1231
11/19/2012
Phase 1/2 Study of PI-3K Inhibition with PX-866 Combined with Vemurafenib (BRAF Inhibitor) in Patients with BRAF-Mutant Cancer Including Advanced Melanoma
TreatmentVICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.